Sanofi Beyfortus nirsevimab
Selected indexed studies
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. (N Engl J Med, 2022) [PMID:35235726]
- Nirsevimab: A Review. (Pediatr Allergy Immunol Pulmonol, 2024) [PMID:38484270]
- Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. (N Engl J Med, 2023) [PMID:38157500]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nirsevimab: A Review. (2024) pubmed
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. (2022) pubmed
- Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. (2025) pubmed
- Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. (2023) pubmed
- Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. (2020) pubmed
- Nirsevimab: First Approval. (2023) pubmed
- Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. (2024) pubmed
- 180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial. (2025) pubmed
- The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access. (2024) pubmed
- Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. (2023) pubmed